LOBAPLATIN: 199 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
199
Total FAERS Reports
8 (4.0%)
Deaths Reported
88
Hospitalizations
199
As Primary/Secondary Suspect
19
Life-Threatening
7
Disabilities
First Report: 20160208 · Latest Report: 20250807
What Are the Most Common LOBAPLATIN Side Effects?
#1 Most Reported
Myelosuppression
84 reports (42.2%)
#2 Most Reported
White blood cell count decreased
21 reports (10.6%)
#3 Most Reported
Platelet count decreased
17 reports (8.5%)
All LOBAPLATIN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Myelosuppression | 84 | 42.2% | 1 | 50 |
| White blood cell count decreased | 21 | 10.6% | 0 | 12 |
| Platelet count decreased | 17 | 8.5% | 1 | 11 |
| Off label use | 15 | 7.5% | 1 | 8 |
| Nausea | 14 | 7.0% | 1 | 5 |
| Neutrophil count decreased | 14 | 7.0% | 0 | 7 |
| Bone marrow failure | 12 | 6.0% | 0 | 5 |
| Vomiting | 11 | 5.5% | 1 | 5 |
| Hepatic function abnormal | 10 | 5.0% | 0 | 1 |
| Rash | 10 | 5.0% | 0 | 3 |
| Asthenia | 9 | 4.5% | 1 | 3 |
| Diarrhoea | 9 | 4.5% | 2 | 3 |
| Anaemia | 8 | 4.0% | 0 | 2 |
| Gastrointestinal disorder | 8 | 4.0% | 0 | 0 |
| Pyrexia | 8 | 4.0% | 0 | 6 |
| Palmar-plantar erythrodysaesthesia syndrome | 7 | 3.5% | 0 | 0 |
| Proteinuria | 7 | 3.5% | 0 | 0 |
| Thrombocytopenia | 7 | 3.5% | 0 | 0 |
| Decreased appetite | 6 | 3.0% | 0 | 3 |
| Drug resistance | 6 | 3.0% | 0 | 0 |
Who Reports LOBAPLATIN Side Effects? Age & Gender Data
Gender: 65.5% female, 34.5% male. Average age: 57.6 years. Most reports from: CN. View detailed demographics →
Is LOBAPLATIN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2016 | 2 | 0 | 1 |
| 2017 | 1 | 0 | 0 |
| 2018 | 5 | 0 | 4 |
| 2019 | 2 | 0 | 1 |
| 2020 | 14 | 2 | 9 |
| 2021 | 14 | 0 | 9 |
| 2022 | 16 | 0 | 8 |
| 2023 | 13 | 0 | 7 |
| 2024 | 38 | 0 | 26 |
| 2025 | 16 | 0 | 11 |
What Is LOBAPLATIN Used For?
| Indication | Reports |
|---|---|
| Lung neoplasm malignant | 19 |
| Hepatocellular carcinoma | 16 |
| Breast cancer | 12 |
| Ovarian cancer | 12 |
| Lung adenocarcinoma | 11 |
| Oesophageal carcinoma | 10 |
| Adenocarcinoma | 9 |
| Chemotherapy | 7 |
| Oesophageal squamous cell carcinoma | 5 |
| Serous cystadenocarcinoma ovary | 5 |
LOBAPLATIN vs Alternatives: Which Is Safer?
LOBAPLATIN vs LOFEXIDINE
LOBAPLATIN vs LOMITAPIDE
LOBAPLATIN vs LOMUSTINE
LOBAPLATIN vs LONAPEGSOMATROPIN-TCGD
LOBAPLATIN vs LONCASTUXIMAB TESIRINE-LPYL
LOBAPLATIN vs LOPERAMIDE
LOBAPLATIN vs LOPINAVIR
LOBAPLATIN vs LOPINAVIR\RITONAVIR
LOBAPLATIN vs LOPRAZOLAM
LOBAPLATIN vs LORATADINE
Official FDA Label for LOBAPLATIN
Official prescribing information from the FDA-approved drug label.